New concepts in opioid analgesia

References

• Stein C. Opioids, sensory systems and chronic pain. Eur J Pharmacol. 2013;716:179–187.
   PubMed Web of Science ®Google Scholar
• Basbaum AI, Bautista DM, Scherrer G, et al. Cellular and molecular mechanisms of pain. Cell. 2009;139(2):267–284.
   PubMed Web of Science ®Google Scholar
• Baron R, Hans G, Dickenson AH. Peripheral input and its importance for central sensitization. Ann Neurol. 2013;74(5):630–636.
   PubMed Web of Science ®Google Scholar
• Richards N, McMahon SB. Targeting novel peripheral mediators for the treatment of chronic pain. Br J Anaesth. 2013;111(1):46–51.
   PubMed Web of Science ®Google Scholar
• Stein C, Hassan AH, Przewlocki R, et al. Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. Proc Natl Acad Sci USA. 1990;87(15):5935–5939.
   PubMed Web of Science ®Google Scholar
• Przewlocki R, Hassan AHS, Lason W, et al. Gene expression and localization of opioid peptides in immune cells of inflamed tissue. Functional role in antinociception. Neuroscience. 1992;48:491–500.
   PubMed Web of Science ®Google Scholar
• Stein C, Hassan AHS, Lehrberger K, et al. Local analgesic effect of endogenous opioid peptides. Lancet. 1993;342:321–324.
   PubMed Web of Science ®Google Scholar
• Schreiter A, Gore C, Labuz D, et al. Pain inhibition by blocking leukocytic and neuronal opioid peptidases in peripheral inflamed tissue. FASEB J. 2012;26(12):5161–5171.
   PubMed Web of Science ®Google Scholar
• Machelska H. Dual peripheral actions of immune cells in neuropathic pain. Arch Immunol Ther Exp (Warsz). 2011;59(1):11–24.
   PubMed Web of Science ®Google Scholar
• Stein C, Machelska H. Modulation of peripheral sensory neurons by the immune system: implications for pain therapy. Pharmacol Rev. 2011;63:860–881.
   PubMed Web of Science ®Google Scholar
• Basso L, Bourreille A, Dietrich G. Intestinal inflammation and pain management. Curr Opin Pharmacol. 2015;25:50–55.
   PubMed Web of Science ®Google Scholar
• Rittner HL, Brack A, Stein C. Pain and the immune system. Br J Anaesth. 2008;101(1):40–44.
   PubMed Web of Science ®Google Scholar
• Roques BP, Fournie-Zaluski MC, Wurm M. Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. Nat Rev Drug Discov. 2012;11(4):292–310.
   PubMed Web of Science ®Google Scholar
• Piomelli D, Sasso O. Peripheral gating of pain signals by endogenous lipid mediators. Nat Neurosci. 2014;17(2):164–174.
   PubMed Web of Science ®Google Scholar
• Schumacher MA, Basbaum AI, Naidu RK. Opioid agonists and antagonists. In: Katzung BG, Trevor AJ, editors. Basic and clinical pharmacology. 13th ed. New York: McGraw-Hill Medical; 2015. p. 531–551.
   Google Scholar
• Fordyce WE. Opioids, pain and behavioral outcomes. APS Journal. 1992;1(4):282–284.
   Google Scholar
• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain–United States, 2016. JAMA. 2016;315(15):1624–1645.
   PubMed Web of Science ®Google Scholar
• Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016;17(2):131–157.
   PubMed Web of Science ®Google Scholar
• Stein C. Opioid receptors. Annu Rev Med. 2016;67:433–451.
   PubMed Web of Science ®Google Scholar
• Cox BM. Recent developments in the study of opioid receptors. Mol Pharmacol. 2013;83(4):723–728.
   PubMed Web of Science ®Google Scholar
• Stevens CW. Bioinformatics and evolution of vertebrate nociceptin and opioid receptors. Vitam Horm. 2015;97:57–94.
   PubMed Web of Science ®Google Scholar
• Law PY, Reggio PH, Loh HH. Opioid receptors: toward separation of analgesic from undesirable effects. Trends Biochem Sci. 2013;38(6):275–282.
   PubMed Web of Science ®Google Scholar
• Wacker D, Stevens RC, Roth BL. How ligands illuminate GPCR molecular pharmacology. Cell. 2017;170(3):414–427.
   PubMed Web of Science ®Google Scholar
• Pasternak GW, Pan YX. Mu opioids and their receptors: evolution of a concept. Pharmacol Rev. 2013;65(4):1257–1317.
   PubMed Web of Science ®Google Scholar
• Bradbury A, Pluckthun A. Reproducibility: standardize antibodies used in research. Nature. 2015;518(7537):27–29.
   PubMed Web of Science ®Google Scholar
• Livingston KE, Traynor JR. Allostery at opioid receptors: modulation with small molecule ligands. Br J Pharmacol. 2018 Jul;175(14):2846–2856.
   Web of Science ®Google Scholar
• Zamponi GW, Currie KP. Regulation of Ca(V)2 calcium channels by G protein coupled receptors. Biochim Biophys Acta. 2013;1828(7):1629–1643.
   PubMed Web of Science ®Google Scholar
• Lüscher C, Slesinger PA. Emerging roles for G protein-gated inwardly rectifying potassium (GIRK) channels in health and disease. Nat Rev Neurosci. 2010;11(5):301–315.
   PubMed Web of Science ®Google Scholar
• Wang HB, Zhao B, Zhong YQ, et al. Coexpression of delta- and mu-opioid receptors in nociceptive sensory neurons. Proc Natl Acad Sci USA. 2010;107(29):13117–13122.
   PubMed Web of Science ®Google Scholar
• Stein C, Küchler S. Targeting inflammation and wound healing by opioids. Trends Pharmacol Sci. 2013;34(6):303–312.
   PubMed Web of Science ®Google Scholar
• Nockemann D, Rouault M, Labuz D, et al. The K channel GIRK2 is both necessary and sufficient for peripheral opioid-mediated analgesia. EMBO Mol Med. 2013;5(8):1263–1277.
   PubMed Web of Science ®Google Scholar
• Dembla S, Behrendt M, Mohr F, et al. Anti-nociceptive action of peripheral mu-opioid receptors by G-beta-gamma protein-mediated inhibition of TRPM3 channels. Elife. 2017;6:pii:e26280.
   Web of Science ®Google Scholar
• Endres-Becker J, Heppenstall PA, Mousa SA, et al. Mu-opioid receptor activation modulates transient receptor potential vanilloid 1 (TRPV1) currents in sensory neurons in a model of inflammatory pain. Mol Pharmacol. 2007;71(1):12–18.
   PubMed Web of Science ®Google Scholar
• Spahn V, Fischer O, Endres-Becker J, et al. Opioid withdrawal increases transient receptor potential vanilloid 1 activity in a protein kinase A-dependent manner. Pain. 2013;154(4):598–608.
   PubMed Web of Science ®Google Scholar
• Quallo T, Alkhatib O, Gentry C, et al. G protein betagamma subunits inhibit TRPM3 ion channels in sensory neurons. Elife. 2017;6:pii:e26138.
   Web of Science ®Google Scholar
• Zöllner C, Stein C. Opioids. Handb Exp Pharmacol. 2007;31–63. 2006/ 11/08ed.
   PubMedGoogle Scholar
• Williams JT, Ingram SL, Henderson G, et al. Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev. 2013;65(1):223–254.
   PubMed Web of Science ®Google Scholar
• Vadivelu N, Mitra S, Hines RL. Peripheral opioid receptor agonists for analgesia: a comprehensive review. J Opioid Manag. 2011;7(1):55–68.
   PubMedGoogle Scholar
• Graham T, Grocott P, Probst S, et al. How are topical opioids used to manage painful cutaneous lesions in palliative care? A critical review. Pain. 2013;154(10):1920–1928.
   PubMed Web of Science ®Google Scholar
• Zeng C, Gao SG, Cheng L, et al. Single-dose intra-articular morphine after arthroscopic knee surgery: a meta-analysis of randomized placebo-controlled studies. Arthroscopy. 2013;29(8):1450–8 e2.
   PubMed Web of Science ®Google Scholar
• Lee LA, Caplan RA, Stephens LS, et al. Postoperative opioid-induced respiratory depression: a closed claims analysis. Anesthesiology. 2015;122(3):659–665.
   PubMed Web of Science ®Google Scholar
• Spahn V, Stein C. Targeting delta opioid receptors for pain treatment: drugs in phase I and II clinical development. Expert Opin Investig Drugs. 2017;26(2):155–160.
   PubMed Web of Science ®Google Scholar
• Pattinson KT. Opioids and the control of respiration. Br J Anaesth. 2008;100(6):747–758.
   PubMed Web of Science ®Google Scholar
• Li Y, van den Pol AN. Mu-opioid receptor-mediated depression of the hypothalamic hypocretin/orexin arousal system. J Neurosci. 2008;28(11):2814–2819.
   PubMed Web of Science ®Google Scholar
• McNicol E. Opioid side effects and their treatment in patients with chronic cancer and noncancer pain. J Pain Palliat Care Pharmacother. 2008;22(4):270–281.
   PubMedGoogle Scholar
• Imam MZ, Kuo A, Ghassabian S, et al. Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression. Neuropharmacology. 2018;131:238–255.
   PubMed Web of Science ®Google Scholar
• Stein C. Pain. In: Cavaillon J-M, Singer M, editors. Inflammation: from molecular and cellular mechanisms to the clinic. Weinheim, Germany: Wiley-VCH; 2018. p. 891–914.
   Google Scholar
• Tabas I, Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science (80- ). 2013;339(6116):166–172.
   PubMed Web of Science ®Google Scholar
• Herz A, Millan MJ, Stein C. Arthritic inflammation in rats as a model of chronic pain: role of opioid systems. NIDA Res Monogr. 1989;95:110–115.
   PubMedGoogle Scholar
• Stein C, Millan MJ, Shippenberg TS, et al. Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. J Pharmacol Exp Ther. 1989;248(3):1269–1275.
   PubMed Web of Science ®Google Scholar
• Stein C, Comisel K, Haimerl E, et al. Analgesic effect of intraarticular morphine after arthroscopic knee surgery. N Engl J Med. 1991;325(16):1123–1126.
   PubMed Web of Science ®Google Scholar
• Stein C. Peripheral mechanisms of opioid analgesia. Anesth Analg. 1993;76:182–191.
   PubMed Web of Science ®Google Scholar
• Hassan AHS, Ableitner A, Stein C, et al. Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue. Neuroscience. 1993;55:185–195.
   PubMed Web of Science ®Google Scholar
• Antonijevic I, Mousa SA, Schäfer M, et al. Perineurial defect and peripheral opioid analgesia in inflammation. J Neurosci. 1995;15(1):165–172.
   PubMed Web of Science ®Google Scholar
• Zöllner C, Shaqura MA, Bopaiah CP, et al. Painful inflammation-induced increase in mu-opioid receptor binding and G-protein coupling in primary afferent neurons. Mol Pharmacol. 2003;64(2):202–210.
   PubMed Web of Science ®Google Scholar
• Spahn V, Del Vecchio G, Labuz D, et al. A nontoxic pain killer designed by modeling of pathological receptor conformations. Science (80- ). 2017;355(6328):966–969.
   PubMed Web of Science ®Google Scholar
• Spahn V, Del Vecchio G, Rodriguez-Gaztelumendi A, et al. Opioid receptor signaling, analgesic and side effects induced by a computationally designed pH-dependent agonist. Sci Rep. 2018;8:8965.
   PubMed Web of Science ®Google Scholar
• Celik MO, Labuz D, Henning K, et al. Leukocyte opioid receptors mediate analgesia via Ca(2+)-regulated release of opioid peptides. Brain Behav Immun. 2016;57:227–242.
   PubMed Web of Science ®Google Scholar
• Stein C, Pflüger M, Yassouridis A, et al. No tolerance to peripheral morphine analgesia in presence of opioid expression in inflamed synovia. J Clin Invest. 1996;98:793–799.
   PubMed Web of Science ®Google Scholar
• Mousa SA, Straub RH, Schäfer M, et al. Beta-endorphin, Met-enkephalin and corresponding opioid receptors within synovium of patients with joint trauma, osteoarthritis and rheumatoid arthritis. Ann Rheum Dis. 2007;66(7):871–879.
   PubMed Web of Science ®Google Scholar
• Likar R, Mousa SA, Philippitsch G, et al. Increased numbers of opioid expressing inflammatory cells do not affect intra-articular morphine analgesia. Br J Anaesth. 2004;93(3):375–380.
   PubMed Web of Science ®Google Scholar
• Zöllner C, Mousa SA, Fischer O, et al. Chronic morphine use does not induce peripheral tolerance in a rat model of inflammatory pain. J Clin Invest. 2008;118(3):1065–1073.
   PubMed Web of Science ®Google Scholar
• Jagla CA, Martus P, Stein C. Peripheral opioid receptor blockade increases postoperative morphine demands - a randomized, double-blind, placebo-controlled trial. Pain. 2014;155:2056–2062.
   PubMed Web of Science ®Google Scholar
• Collett BJ. Opioid tolerance: the clinical perspective. Br J Anaesth. 1998;81(1):58–68.
   PubMed Web of Science ®Google Scholar
• Rozen D, Grass GW. Perioperative and intraoperative pain and anesthetic care of the chronic pain and cancer pain patient receiving chronic opioid therapy. Pain Pract. 2005;5(1):18–32.
   PubMedGoogle Scholar
• Hill R, Disney A, Conibear A, et al. The novel mu-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception. Br J Pharmacol. 2018;175(13):2653–2661.
   PubMed Web of Science ®Google Scholar
• Galer BS, Lee D, Ma T, et al. MorphiDex (morphine sulfate/dextromethorphan hydrobromide combination) in the treatment of chronic pain: three multicenter, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance. Pain. 2005;115(3):284–295.
   PubMed Web of Science ®Google Scholar
• Schneider JP, Kirsh KL. Defining clinical issues around tolerance, hyperalgesia, and addiction: a quantitative and qualitative outcome study of long-term opioid dosing in a chronic pain practice. J Opioid Manag. 2010;6(6):385–395.
   PubMedGoogle Scholar
• Collin E, Poulain P, Gauvain-Piquard A, et al. Is disease progression the major factor in morphine ‘tolerance’ in cancer pain treatment? Pain. 1993;55(3):319–326.
   PubMed Web of Science ®Google Scholar
• Smith SM, Dart RC, Katz NP, et al. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain. 2013;154(11):2287–2296.
   PubMed Web of Science ®Google Scholar
• Compton P, Miotto K, Elashoff D. Precipitated opioid withdrawal across acute physical dependence induction methods. Pharmacol Biochem Behav. 2004;77(2):263–268.
   PubMed Web of Science ®Google Scholar
• Vowles KE, McEntee ML, Julnes PS, et al. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156(4):569–576.
   PubMed Web of Science ®Google Scholar
• Schuchat A, Houry D, Guy GP Jr. New data on opioid use and prescribing in the United States. JAMA. 2017;318(5):425–426.
   PubMed Web of Science ®Google Scholar
• Psaty BM, Merrill JO. Addressing the opioid epidemic - opportunities in the postmarketing setting. N Engl J Med. 2017;376(16):1502–1504.
   PubMed Web of Science ®Google Scholar
• Szigethy E, Knisely M, Drossman D. Opioid misuse in gastroenterology and non-opioid management of abdominal pain. Nat Rev Gastroenterol Hepatol. 2018;15(3):168–180.
   PubMed Web of Science ®Google Scholar
• Haffajee RL, Mello MM. Drug companies’ liability for the opioid epidemic. N Engl J Med. 2017;377(24):2301–2305.
   PubMed Web of Science ®Google Scholar
• Fishbain DA, Cole B, Lewis JE, et al. Do opioids induce hyperalgesia in humans? An evidence-based structured review. Pain Med. 2009;10(5):829–839.
   PubMed Web of Science ®Google Scholar
• Comelon M, Raeder J, Stubhaug A, et al. Gradual withdrawal of remifentanil infusion may prevent opioid-induced hyperalgesia. Br J Anaesth. 2016;116(4):524–530.
   PubMed Web of Science ®Google Scholar
• Fletcher D, Martinez V. Opioid-induced hyperalgesia in patients after surgery: a systematic review and a meta-analysis. Br J Anaesth. 2014;112(6):991–1004.
   PubMed Web of Science ®Google Scholar
• Angst MS. Intraoperative use of remifentanil for TIVA: postoperative pain, acute tolerance, and opioid-induced hyperalgesia. J Cardiothorac Vasc Anesth. 2015;29(Suppl 1):S16–22.
   PubMedGoogle Scholar
• Eriksen J, Sjogren P, Bruera E, et al. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain. 2006;125(1–2):172–179.
   PubMed Web of Science ®Google Scholar
• Reinecke H, Weber C, Lange K, et al. Analgesic efficacy of opioids in chronic pain: recent meta-analyses. Br J Pharmacol. 2015;172(2):324–333.
   PubMed Web of Science ®Google Scholar
• Stein C. Opioid treatment of chronic nonmalignant pain. Anesth Analg. 1997;84(4):912–914.
   PubMed Web of Science ®Google Scholar
• Mura E, Govoni S, Racchi M, et al. Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside? J Pain Res. 2013;6:331–353.
   PubMed Web of Science ®Google Scholar
• Walter C, Doehring A, Oertel BG, et al. Mu-opioid receptor gene variant OPRM1 118 A>G: a summary of its molecular and clinical consequences for pain. Pharmacogenomics. 2013;14(15):1915–1925.
   PubMed Web of Science ®Google Scholar
• Matic M, De Wildt SN, Tibboel D, et al. Analgesia and opioids: a pharmacogenetics shortlist for implementation in clinical practice. Clin Chem. 2017;63(7):1204–1213.
   PubMed Web of Science ®Google Scholar
• Hauser AS, Chavali S, Masuho I, et al. Pharmacogenomics of GPCR drug targets. Cell. 2018;172(1–2):41–54 e19.
   PubMed Web of Science ®Google Scholar
• Busch-Dienstfertig M, Roth CA, Stein C. Functional characteristics of the naked mole rat mu-opioid receptor. PloS One. 2013;8(11):e79121.
   PubMed Web of Science ®Google Scholar
• Chan HCS, McCarthy D, Li J, et al. Designing safer analgesics via mu-opioid receptor pathways. Trends Pharmacol Sci. 2017;38(11):1016–1037.
   PubMed Web of Science ®Google Scholar
• Vardy E, Sassano MF, Rennekamp AJ, et al. Single amino acid variation underlies species-specific sensitivity to amphibian skin-derived opioid-like peptides. Chem Biol. 2015;22(6):764–775.
   PubMedGoogle Scholar
• Fidecka S, Malec D, Langwinski R. Central action of narcotic analgesics. II. Locomotor activity and narcotic analgesics. Pol J Pharmacol Pharm. 1978;30(1):5–16.
   PubMedGoogle Scholar
• Noble F, Cox BM. Differences among mouse strains in the regulation by mu, delta 1 and delta 2 opioid receptors of striatal adenylyl cyclases activated by dopamine D1 or adenosine A2a receptors. Brain Res. 1996;716(1–2):107–117.
   PubMed Web of Science ®Google Scholar
• Noble F, Cox BM. Differential regulation of D1 dopamine receptor- and of A2a adenosine receptor-stimulated adenylyl cyclase by mu-, delta 1-, and delta 2-opioid agonists in rat caudate putamen. J Neurochem. 1995;65(1):125–133.
   PubMed Web of Science ®Google Scholar
• Huang P, Chen C, Liu-Chen LY. Detection of mu opioid receptor (MOPR) and its glycosylation in rat and mouse brains by western blot with anti-muC, an affinity-purified polyclonal anti-MOPR antibody. Methods Mol Biol. 2015;1230:141–154.
   PubMedGoogle Scholar
• Sirohi S, Aldrich JV, Walker BM. Species differences in the effects of the kappa-opioid receptor antagonist zyklophin. Alcohol. 2016;51:43–49.
   PubMed Web of Science ®Google Scholar
• Kruegel AC, Gassaway MM, Kapoor A, et al. Synthetic and receptor signaling explorations of the mitragyna alkaloids: mitragynine as an atypical molecular framework for opioid receptor modulators. J Am Chem Soc. 2016;138(21):6754–6764.
   PubMed Web of Science ®Google Scholar
• Rowan MP, Szteyn K, Doyle AP, et al. Beta-arrestin-2-biased agonism of delta opioid receptors sensitizes transient receptor potential vanilloid type 1 (TRPV1) in primary sensory neurons. Mol Pain. 2014;10:50.
   PubMed Web of Science ®Google Scholar
• Corder G, Tawfik VL, Wang D, et al. Loss of mu opioid receptor signaling in nociceptors, but not microglia, abrogates morphine tolerance without disrupting analgesia. Nat Med. 2017;23(2):164–173.
   PubMed Web of Science ®Google Scholar
• Albert-Vartanian A, Boyd MR, Hall AL, et al. Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? J Clin Pharm Ther. 2016;41(4):371–382.
   PubMed Web of Science ®Google Scholar
• Becker WC, Fiellin DA. Abuse-deterrent opioid formulations - putting the potential benefits into perspective. N Engl J Med. 2017;376(22):2103–2105.
   PubMed Web of Science ®Google Scholar
• Yekkirala AS, Roberson DP, Bean BP, et al. Breaking barriers to novel analgesic drug development. Nat Rev Drug Discov. 2017;16(8):545–564.
   PubMed Web of Science ®Google Scholar
• Raffa RB, Taylor R Jr., Pergolizzi JV Jr. Sequestered naltrexone in sustained release morphine or oxycodone - a way to inhibit illicit use? Expert Op Drug Safety. 2014;13(2):181–190.
   PubMed Web of Science ®Google Scholar
• Bonnard E, Poras H, Nadal X, et al. Long-lasting oral analgesic effects of N-protected aminophosphinic dual ENKephalinase inhibitors (DENKIs) in peripherally controlled pain. Pharmacol Res Perspect. 2015;3(2):e00116.
   PubMed Web of Science ®Google Scholar
• Basso L, Boue J, Auge C, et al. Mobilization of CD4+ T lymphocytes in inflamed mucosa reduces pain in colitis mice: toward a vaccinal strategy to alleviate inflammatory visceral pain. Pain. 2018 Feb;159(2):331–341.
   Web of Science ®Google Scholar
• Schmid CL, Kennedy NM, Ross NC, et al. Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell. 2017;171(5):1165–75 e13.
   PubMed Web of Science ®Google Scholar
• Montandon G, Ren J, Victoria NC, et al. G-protein-gated inwardly rectifying potassium channels modulate respiratory depression by opioids. Anesthesiology. 2016;124(3):641–650.
   PubMed Web of Science ®Google Scholar
• Soergel DG, Subach RA, Sadler B, et al. First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol. 2014;54(3):351–357.
   PubMed Web of Science ®Google Scholar
• Charfi I, Audet N, Bagheri Tudashki H, et al. Identifying ligand-specific signalling within biased responses: focus on delta opioid receptor ligands. Br J Pharmacol. 2015;172(2):435–448.
   PubMed Web of Science ®Google Scholar
• Altarifi AA, David B, Muchhala KH, et al. Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents. J Psychopharmacol. 2017;31(6):730–739.
   PubMed Web of Science ®Google Scholar
• Viscusi ER, Webster L, Kuss M, et al. A randomized, phase 2 study investigating TRV130, a biased ligand of the mu-opioid receptor, for the intravenous treatment of acute pain. Pain. 2016;157(1):264–272.
   PubMed Web of Science ®Google Scholar
• Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–779.
   PubMed Web of Science ®Google Scholar
• Valverde A, Gunkel CI. Pain management in horses and farm animals. J Vet Emerg Crit Care. 2005;15(4):295–307.
   Web of Science ®Google Scholar
• Wei J, Lei GH, Gao SG, et al. Single-dose intra-articular bupivacaine versus morphine after arthroscopic knee surgery: a meta-analysis of randomized-controlled studies. Clin J Pain. 2014;30(7):630–638.
   PubMed Web of Science ®Google Scholar
• Machelska H, Schroff M, Oswald D, et al. Peripheral non-viral MIDGE vector-driven delivery of beta-endorphin in inflammatory pain. Mol Pain. 2009;5:72.
   PubMed Web of Science ®Google Scholar
• Raja SN. Modulating pain in the periphery: gene-based therapies to enhance peripheral opioid analgesia: bonica lecture, ASRA 2010. Reg Anesth Pain Med. 2012;37(2):210–214.
   PubMed Web of Science ®Google Scholar
• Binder W, Machelska H, Mousa S, et al. Analgesic and antiinflammatory effects of two novel kappa-opioid peptides. Anesthesiology. 2001;94(6):1034–1044.
   PubMed Web of Science ®Google Scholar
• Machelska H, Pflüger M, Weber W, et al. Peripheral effects of the kappa-opioid agonist EMD 61753 on pain and inflammation in rats and humans. J Pharmacol Exp Ther. 1999;290(1):354–361.
   PubMed Web of Science ®Google Scholar
• Dahan A, Van Dorp E, Smith T, et al. Morphine-6-glucuronide (M6G) for postoperative pain relief. Eur J Pain. 2008;12(4):403–411.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Rodriguez S, Quadir MA, Gupta S, et al. Polyglycerol-opioid conjugate produces analgesia devoid of side effects. Elife. 2017;6:e27081.
   PubMed Web of Science ®Google Scholar
• Del Vecchio G, Spahn V, Stein C. Novel opioid analgesics and side effects. ACS Chem Neurosci. 2017;8(8):1638–1640.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Gaztelumendi A, Spahn V, Labuz D, et al. Analgesic effects of a novel pH-dependent mu-opioid receptor agonist in models of neuropathic and abdominal pain. Pain. 2018. In press.
   PubMedGoogle Scholar
• Li JG, Chen C, Yin J, et al. ASP147 in the third transmembrane helix of the rat mu opioid receptor forms ion-pairing with morphine and naltrexone. Life Sci. 1999;65(2):175–185.
   PubMed Web of Science ®Google Scholar
• Dosen-Micovic L, Ivanovic M, Micovic V. Steric interactions and the activity of fentanyl analogs at the mu-opioid receptor. Bioorg Med Chem. 2006;14(9):2887–2895.
   PubMed Web of Science ®Google Scholar
• Mogil JS, Davis KD, Derbyshire SW. The necessity of animal models in pain research. Pain. 2010;151(1):12–17.
   PubMed Web of Science ®Google Scholar
• Davis KD, Flor H, Greely HT, et al. Brain imaging tests for chronic pain: medical, legal and ethical issues and recommendations. Nat Rev Neurol. 2017;13(10):624–638.
   PubMed Web of Science ®Google Scholar
• Berge OG. Predictive validity of behavioural animal models for chronic pain. Br J Pharmacol. 2011;164(4):1195–1206.
   PubMed Web of Science ®Google Scholar
• Wieschowski S, Chin WWL, Federico C, et al. Preclinical efficacy studies in investigator brochures: do they enable risk-benefit assessment? PLoS Biol. 2018;16(4):e2004879.
   PubMed Web of Science ®Google Scholar